Rocket Pharmaceuticals Inc Stock News

Rocket Pharmaceuticals Inc (RCKT) shares closed today at 1.4% above its 52 week low of $23.35, giving the company a market cap of $1B. The stock is currently down 56.8% year-to-date, down 23.9% over the past 12 months, and down 1.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 19.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 80.5% The company's stock price performance over the past 12 months beats the peer average by -5.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)s traded shares stood at 0.35 million during the last session, with the companys beta value hitting 1.68. At the close of trading, the stocks price was $27.87, to imply an increase of 2.99% or $0.81 in intraday trading. The RCKT shares 52-week high remains $67.48, putting it -142.12% down since that Should You Expect Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) To Recover From Its 11.7% Gain From Highs? Read More »

Bank of America Corp DE lessened its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 32.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 356,094 shares of the biotechnology companys stock after selling 173,636 shares during the period. Bank of America Corp DE owned approximately 0.56% []

Related Stocks: PHVS , FOLD , KNTE , IOVA , AKUS , LUNG , BSX , VECT , RCKT , ANNX , INZY , PTGX , LEGN , EAR , ABCL , XENT ,

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare c

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorder

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorder

Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company developing gene therapies with a focus on direct on-target mechanisms of action for rare and devastating orphan d

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorder

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorder

The FDA has lifted the clinical hold on Rocket Pharmaceuticals Inc's (NASDAQ:RCKT) Phase 1 trial of RP-A501 (gene therapy) for Danon Disease, allowing patient enrollment to resume.  The hold was

Rocket Pharmaceuticals, Inc. (RCKT) CEO Gaurav Shah on Q2 2021 Results - Earnings Call Transcript

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced positive data from its Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and Pyruvate Kinase Deficiency (PKD) gene therapy progr

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.